“…Indeed, it was mentioned earlier that a fraction of TPMT wild-type patients can still have intermediate TPMT-activity and that other factors play a role in the development of this ADR 16,33,36. Moreover, other side effects such as hepatotoxicity, pancreatitis, nausea and vomiting cannot be predicted by TPMT testing 1,14,65. The adoption of pretreatment TPMT screening seems to vary according to discipline, as reported by one survey, with 94% of dermatologists, 60% of gastroenterologists and only 47% rheumatologists requesting it 76.…”